Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Point Of Care Infectious Disease Diagnostics Market 2025 - Coherent Market InsightsPoint of Care Infectious Disease Diagnostics Market Report Analyses competitive environment such as key players, future trends, growths, challenges and acquisitions in the market.
Global Point of Care Infectious Disease Diagnostics Market - Insights Point-of-care (POC) diagnostic testing allows patient diagnoses in the physician's office, home, an ambulance, the field, or in the hospital. POC allows rapid and timely treatment to patient. Infectious diseases often need to be diagnosed early, as they can become fatal against immunity system. Various novel technologies are used in POC diagnostics such as lateral flow, agglutination assays, and solid phase that are integrated with innovative features such as portability of handheld devices. The U.S. Food & Drug Administration (FDA) is responsible for overseeing all the activities associated with marketing of point of care diagnostic products. Along with U.S. FDA, Browse Research Report: https://www.coherentmarketinsights.com/ Market Dynamics- Drivers The global point of care infectious disease diagnostics market was valued at US$ 1,764.6 million in 2016 and is expected to witness a robust CAGR of 14.5% over the forecast period (2017 – 2025). To learn more about this report, request a sample copy* * The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology. Request a sample copy of this report: https://www.coherentmarketinsights.com/ MArket Initiatives and funding from individual organizations for point-of-care infectious disease diagnostics is expected to boost the market growth over the forecast period Key organizations and governmental institutes are involved in research and development for infectious diseases to provide effective diagnostic and treatment options. For instance, QuantuMDx Group received funding from Bill & Melinda Gates Foundation to develop and test company's CAPTURE-XT pathogen concentration technology and Q-POC molecular diagnostic platform for rapid low cost detection of tuberculosis in 2016. In January 2018, University of Glasgow-led project received US$ 1.85 million funding, which is a part of Global Challenges Research Fund (GCRF). This project will develop new tests for parasitic diseases and point-of-care testing in remote locations to help enable rapid diagnosis, and rapid treatment. Buy-Now this research report: https://www.coherentmarketinsights.com/ End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|